
-
Indian army says new exchange of gunfire with Pakistan
-
Epstein accuser Virginia Giuffre takes own life in Australia: family
-
Hundreds of buildings damaged, dozens injured in 6.3 Ecuador quake
-
India and Pakistan's Kashmir fallout hits economy too
-
Francis's funeral to be grand farewell to 'pope of the poor'
-
Pogacar faces defiant Evenepoel at Liege-Bastogne-Liege
-
Chelsea eye great escape against Barcelona in Women's Champions League
-
Iran, US to hold new round of high-level nuclear talks
-
'Energy and effort' pay off for Reds as Blues' woes continue
-
Albatross and closing birdie lift China's Liu to LPGA Chevron lead
-
On the horizon? Wave of momentum for high seas treaty
-
Developing countries should fast-track US trade deals: World Bank president
-
Grizzlies' Morant 'doubtful' for must-win game 4 v Thunder
-
Trump in Rome for pope funeral in first foreign trip of new term
-
Trump says Russia-Ukraine deal 'very close' after new Kremlin talks
-
US rookies lead PGA pairs event with McIlroy and Lowry in hunt
-
Trump tariff promises get a reality check
-
Warriors coach Kerr 'relatively optimistic' injured Butler will play game 3
-
Postecoglou hopes 'Stonecutter's Credo' can inspire Spurs
-
PSG lose unbeaten Ligue 1 record ahead of Arsenal showdown
-
Venezuela accuses El Salvador president of 'human trafficking'
-
Own goal takes Sundowns to African final against Pyramids
-
Scores of buildings damaged, 20 injured in Ecuador quake
-
US stocks extend rally as market eyes busy calendar next week
-
Pope's death triggers surge of disinformation he fought against
-
Rovanpera takes control of Rally Islas Canarias
-
Zelensky insists Crimea is Ukrainian as US envoy meets Putin
-
Patel and Mendis help Sunrisers beat Kings in Dhoni's 400th T20
-
Copa del Rey ref statements 'unacceptable': Real Madrid after boycotting final build-up
-
Insurance CEO's accused killer pleads not guilty to federal murder charges
-
FBI arrests Wisconsin judge for shielding undocumented migrant
-
Brazil ex-president Collor de Mello jailed for corruption
-
Zelensky insists Crimea 'belongs' to Ukraine as US envoy meets Putin
-
Real Madrid boycott Copa del Rey build-up over referee complaints
-
Trinidad and Tobago votes for parliament, PM, with opposition in lead
-
IMF chief hails 'constructive' Spring Meetings held under tariff uncertainty
-
Iran FM Araghchi in Oman ahead of nuclear talks with US
-
Dozens of buildings destroyed, 20 injured in Ecuador quake
-
Young Barca must 'enjoy' Real Madrid Copa final fight: Flick
-
Pakistan and India border closure separates families
-
Brazil's Bolsonaro 'stable' after post-surgery setback
-
Catholics in secular Cuba hail Francis as 'bridge'
-
US envoy Witkoff, Putin discuss 'possibility' of direct Russia-Ukraine talks
-
Community seeks answers after French school knife killing
-
German prosecutors seek jail terms in VW 'dieselgate' trial
-
Sabalenka makes winning start at Madrid Open
-
EU, US should de-escalate and negotiate trade deal: IMF Europe director
-
Russia accuses Ukraine of killing general in car bombing
-
Emery wants FA Cup glory and Champions League berth for Villa
-
Buildings destroyed, one injured in Ecuador quake

Trial of new Covid treatment yields encouraging results: study
A single-injection antiviral treatment for newly-infected Covid-19 patients reduced the risk of hospitalization by half in a large-scale clinical trial, according to a study published on Wednesday.
Stanford University professor Jeffrey Glenn, coauthor of the study published in the New England Journal of Medicine (NEJM), said the new drug "showed profound benefits for vaccinated and unvaccinated people alike."
While the number of Americans dying daily of coronavirus has fallen to around 500, treatments for the disease remain limited. One of the most common, Paxlovid made by Pfizer, involves taking 30 pills over five days.
The new treatment involves a single dose of pegylated lambda-interferon, a synthetic version of a naturally occurring protein that infected cells secrete to defend against viral infection.
"What it does is it binds receptors on the surfaces of cells that activate our own antiviral defense mechanisms," said Glenn, a professor of medicine, microbiology and immunology who heads the Stanford Biosecurity and Pandemic Preparedness Initiative.
"So if a virus has infected the cell it will turn on processes that aim to destroy the virus's replication," he said. "It will also send signals to neighboring cells to warn them viruses are on their way and get ready to defend yourself."
Receptors for interferon lambda are primarily in the linings of the lungs, airways and intestine -- the main places Covid strikes.
"We're turning on these antiviral mechanisms in the cells, the lung, where the infection is happening," Glenn said.
The Phase 3 trial of the drug, conducted between June 2021 and February 2022, involved nearly 2,000 patients with Covid symptoms in Brazil and Canada, about 85 percent of whom had been vaccinated.
A total of 931 newly-infected Covid patients were given a single injection of interferon lambda while 1,018 participants were given a placebo.
The risk of Covid-19–related hospitalization or death from any cause was 47 percent lower in the interferon group than in the placebo group, according to the researchers.
Twenty-five of the 931 people who received the injection within seven days of exhibiting Covid symptoms were hospitalized compared with 57 of the 1,018 who received the placebo.
Vaccinated patients treated with interferon lambda experienced a 51 percent reduction in hospitalization relative to the placebo group.
There was an 89 percent reduction in hospitalization among unvaccinated patients treated within the first three days of the onset of Covid symptoms compared with the placebo group.
- Developed for hepatitis D -
Glenn said interferon lambda proved effective against all Covid variants tested, including Omicron, and side effects in the group receiving the injections were no greater than among the placebo recipients.
Glenn is the founder of a small biotechnology company called Eiger Biopharmaceuticals that acquired interferon lambda to develop drugs for hepatitis delta virus.
"When Covid came, I said this would be the perfect drug for Covid," said Glenn, who left the Palo Alto-based company but remains on the board of directors and is an equity holder.
Eiger sought an emergency use authorization for interferon lambda from the US Federal Drug Administration (FDA) for Covid treatment last year but it was not granted.
That was "very frustrating," Glenn said, but he was hopeful publication of the study in the NEJM "will help encourage regulators here and around the world to find a way to get lambda into patients as soon as possible."
P.Costa--AMWN